Inhalt

in Literatur blättern

  • Detailansicht

Bibliographische Angaben zur Publikation

Cochleo-vestibular clinical findings among drug resistant Tuberculosis Patients on therapy: A pilot study


Autor/in:

Ramma, Lebogang; Ibekwe, Titus S.


Herausgeber/in:

k. A.


Quelle:

International Archives of Medicine, 2012, Volume 5, London: BioMed Central, ISSN: 1755-7682 (online)


Jahr:

2012



Link(s):


Link zu dem Beitrag (HTML)
Link zu dem Beitrag (PDF | 181 KB)


Abstract:


Background:

To investigate the Cochleo-vestibular clinical and audiometric findings in Multi and Extreme Drug Resistance(MDR and XDR) tuberculosis(TB) patients on treatment and make recommendations.

Methods:

A cross-sectional study of adult MDR and XDR-TB patients was conducted in a general hospital in Cape-Town-South-Africa. Ethical approval was secured and all consenting patients administered with pretested and validated questionnaire under the guidance of International Classification of Functioning, Disability and Health (ICF) Checklist-version-2.1a. Audiometric evaluation included: Otoscopy, Diagnostic Audiometry and Tympanometry. The data analyses were done with SPSS version 16, Chi-square and StatCalc-7.

Results:

Fifty-three adults, ages 18-60 (mean-33 years) comprising 26 males and 27 females participated in the study. Hospital stay duration varied from 1-18 months (mean-6 months) and all were on anti-Koch's second line drugs (regimen 2). MDR TB group were 45(85%) and XDR 8(15%). Vertigo was the most common vestibular symptoms, 24(45%) whereas, tinnitus 23(42%) and hearing loss 13(25%) were most frequent auditory complaints. Bilateral sensorineural hearing losses of varying degrees were confirmed in 23(47%).There was no association between gender and age with hearing loss [?2 (P = 0.16, ? = 0.05) and (p = 0.13, ? = 0.05)]. Furthermore, MDR and XTR TB groups [20/42 Vs 3/8; Z = 0.46 and P = 0.64], showed no difference in pattern of the hearing losses.

Conclusions:

A multi-disciplinary close surveillance of MDR and XDR TB patients on therapy is imperative. Finally, researches into therapeutic trials on antidotes and potent safer substitutes for aminoglycosides in the management are recommended.


Weitere Informationen:


Schlagworte:
Informationen in der ICF:


Dokumentart:


Zeitschriftenbeitrag / Forschungsergebnis / Online-Publikation




Bezugsmöglichkeit:


International archives of medicine (Open Access)
Homepage: https://link.springer.com/journal/13038

Um Literatur zu beziehen, wenden Sie sich bitte an Bibliotheken, die Herausgeber, den Verlag oder an den Buch- und Zeitschriftenhandel.



Referenznummer:

R/ZA5091


Informationsstand: 10.05.2012

in Literatur blättern